Tejaswini Kulkarni

Intensive Care Medicine

619 19th St S
Birmingham, AL 35249

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Reply to Sun et al.: Interpreting Benefit in ELEVATE-IPF.

Reply to Sun et al.: Interpreting Benefit in ELEVATE-IPF.

Journal: American journal of respiratory and critical care medicine

Published: April 21, 2026

Reply to Sun et al.: Interpreting benefit in ELEVATE-IPF.

Reply to Sun et al.: Interpreting benefit in ELEVATE-IPF.

Journal: American journal of respiratory and critical care medicine

Published: April 21, 2026

Post-progression treatment patterns in systemic autoimmune rheumatic disease-associated interstitial lung disease: insights from a US retrospective, observational study.

Post-progression treatment patterns in systemic autoimmune rheumatic disease-associated interstitial lung disease: insights from a US retrospective, observational study.

Journal: BMJ open

Published: April 07, 2026

Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study.

Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study.

Journal: Nature communications

Published: February 27, 2026

Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial.

Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial.

Journal: American journal of respiratory and critical care medicine

Published: December 12, 2025

Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial.

Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial.

Journal: American journal of respiratory and critical care medicine

Published: December 12, 2025

Challenging the status quo for therapeutic clinical trials in fibrotic interstitial lung diseases.

Challenging the status quo for therapeutic clinical trials in fibrotic interstitial lung diseases.

Journal: Thorax

Published: December 07, 2025

Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study.

Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

Screening for Pulmonary Hypertension in Interstitial Lung Disease: Preliminary Results from the PHINDER Study.

Screening for Pulmonary Hypertension in Interstitial Lung Disease: Preliminary Results from the PHINDER Study.

Journal: Advances in therapy

Published: November 10, 2025

Pulmonary Hypertension Associated with Interstitial Lung Disease: Screening and Epidemiology.

Pulmonary Hypertension Associated with Interstitial Lung Disease: Screening and Epidemiology.

Journal: ATS scholar

Published: October 01, 2025

Shaping the landscape of interstitial lung disease in idiopathic inflammatory myopathies: state of the art, evidence gaps and a need for clinical trials.

Shaping the landscape of interstitial lung disease in idiopathic inflammatory myopathies: state of the art, evidence gaps and a need for clinical trials.

Journal: Clinical and experimental rheumatology

Published: October 01, 2025

Reply to Borrás-Blasco et al.: How Adherence Shapes Persistence in IPF Treatment: A Call for Real-World Insight.

Reply to Borrás-Blasco et al.: How Adherence Shapes Persistence in IPF Treatment: A Call for Real-World Insight.

Journal: Annals of the American Thoracic Society

Published: September 12, 2025

Showing 1-12 of 59

Last Updated: 09/26/2026